اثر آستاگزانتين طبيعي در پيشگيري و درمان انسفالوميليت تجربي خودايمن (EAE)

The effect of natural Astaxanthin on the prevention and treatment of experimental autoimmune encephalomyelitis (EAE)

فافيا رودوزيما حاوي كاروتنوئيد آستاگزانتين مي باشد كه خاصيت آنتي اكسيدانتي و ضدالتهابي قوي دارد. در مطالعه پيش‌رو اثر آستاگزانتين فافيا رودوزيما در موش مدل بيماري مالتيپل اسكلروزيس (MS)مورد بررسي قرار گرفت. مدل بيماري MS يا آنسفالوميليت تجربي خود ايمن ((EAE با استفاده از پپتيد MOG35-55 در موش‌هاي ماده C57BL/6 ايجاد گرديد. براي اين مطالعه چهار گروه در نظر گرفته شدموشهاي گروه كنترل طبيعي، گروه بيمار، گروه پيشگيري دريافت كننده آستاگزانتين يك هفته قبل از القا بيماري و گروه‌هاي درماني كه آستاگزانتين را پس از ايمونيزاسيون و ظهور اولين نشانه بيماري دريافت كرده بودند. هر گروه شامل 7 سر موش بود. مصرف آستاگزانتين تا 35 روز پس از ايمونيزاسيون ادامه يافت و هر روز به مقدار mg/kg400 آستاگزانتين فافيا رودوزيما مصرف مي‌شد به اين صورت كه پلت مصرفي روزانه به اين مقدار آستاگزانتين مخلوط مي‌شد.علائم باليني و ميانگين وزن بدن روزانه بررسي مي‌شد. همچنين ميزان تكثير لنفوسيت‌ها به وسيله آزمون MTT، ميزان توليد سايتوكاين‌التهابي IL23 و ضد التهابي IL4 به وسيله ELISA سنجيده شد.

Phaffia rhodozyma contains the carotenoid astaxanthin, which has strong antioxidant activity and anti-inflammatory properties. In the present study, the Effects of astaxanthin produced by Phaffia rhodozyma on multiple sclerosis (MS) model of mice were investigated. Mice model of MS or experimental autoimmune encephalomyelitis (EAE) was developed using MOG35-55 peptide in female C57BL/6 mice. Four groups were considered for this study: normal control group mice, EAE group, prevention group mice that received astaxanthin a week before immunization and treatment group that received astaxanthin after immunization at the time of first sign of EAE. Each group consisted of 7 mice. Astaxanthin consumption up to 35 days after immunization continued. Each day 400 mg of Phaffia rhodozyma astaxanthin was consumed in this way, the daily consumption pellet was mixed with this amount of astaxanthin. Daily clinical signs and mean body weight were monitored then proliferation was measured by MTT assay; IL23 level (proinflammatory cytokines) and IL4 level (anti-inflammatory cytokine) were measured by ELISA. Observations showed that the mean disease severity in all experimental groups was significantly reduced compared to the EAE group and the mean body weight in the experimental groups had a significant increase compared to the EAE group (P<0.001). Also, Astaxanthin administration significantly reduced the level of inflammatory cytokine, IL23 and increased the level of anti-inflammatory cytokine, IL4 in both experimental groups (P<0.001). The results of MTT test also show a decrease in Proliferation index (The rate of proliferation of immune cells) in both prevention and treatment groups. P<0.001